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Adrenal gland metastases are a common clinical 
scenario, particularly in patients with lung cancer, 
renal cell carcinoma and melanoma. Post-mor-
tem studies of patients with cancer demonstrate 
an incidence of adrenal metastases between 13% 
and 27%. The management of symptomatic or 
oligometastatic scenarios is challenging. Gener-
ally, surgical resection has been the standard of 
care [1, 3]. Local ablative procedures such as ra-
diofrequency ablation, microwave ablation and 
cryotherapy have also been used as an alternative 
to adrenalectomy [3, 4]. However, in some situ-
ations, it is not feasible due to patients’ medical 
comorbidities, tumor size, burden of metastatic 
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background: stereotactic body radiation therapy (sBrT) as a form of noninvasive treatment that is becoming increasingly 
used to manage cancers with adrenal gland metastases. There is a paucity of data on safety and efficacy of this modality. The 
aim of the study was to evaluate the safety and efficacy of adrenal gland sBrT in oligometastatic and oligoprogressive disease.
Materials and methods: In this retrospective study, we performed a single-institution analysis of 26 adrenal lesions from 23 
patients with oligometastatic or oligoprogressive disease treated from 2013 to 2019 with the goal of achieving durable lo-
cal control. palliative cases were excluded. radiation dosimetry data was collected. Kaplan Meier product estimator and cox 
proportional hazards regression analysis were used for statistical analysis.
results: The median dose was 36 Gy in 3 fractions (range: 24–50 Gy and 3–6 fractions) with a median biologically effective 
dose (BeD10) of 72 (range: 40–100). 1-year local control rate was 80% and median local control was not achieved due to a 
low number of failures. 1- and 2-year overall survival rates were 66% and 32%. Toxicity was mild with only one case of grade 
2 nausea and no grade 3–5 toxicity. higher neutrophil to lymphocyte ratio was associated with worse overall survival and a 
trend toward worse progression-free survival. In addition, worse performance status and lower BeD10 were associated with 
worse survival. No such association could be shown for primary tumor location, histology, size or stage.
conclusion: adrenal sBrT for oligometastatic or oligoprogressive disease is a safe and effective form of treatment.
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disease or preference for noninvasive methods. 
Radiotherapy can offer a noninvasive means of 
treating such malignancies. While conventional 
palliative external beam radiotherapy may lead 
to pain improvement, it has a suboptimal local 
control [5].
Oligometastatic and oligoprogressive dis-
ease has been shown to be a distinct entity from 
polymetastatic disease (widely metastatic cancer) 
with a much better prognoses than those with 
diffuse metastastases [6, 7]. While local treat-
ment for metastatic disease has been traditionally 
done exclusively for palliation of pain, bleeding 
and obstructive symptoms, several recent phase 
2 studies have shown feasibility and improved 
progression-free survival and overall survival 
in oligometastatic patients treated aggressively 
with stereotactic body radiation therapy (SBRT) 
[8–10]. SBRT is a method that allows for a pre-
cise tumor targeting while avoiding normal tissue 
structures using advanced technology that allows 
for delivering higher radiotherapy doses with each 
fraction [11].
There is very limited prospective data on the 
efficacy of stereotactic radiotherapy in treatment 
of adrenal tumors as the SBRT studies in oligo-
metastatic disease included a wide variety of tumor 
locations [9, 10, 12]. However, multiple retrospec-
tive single institution studies have been published. 
While these showed a favorable local control rate 
and toxicity profile, the studies are small and with 
heterogeneous patient population, so additional 
reports are needed to confirm the safety and ef-
ficacy of adrenal SBRT [13–42]. Moreover, the data 
regarding radiotherapy planning and organ at risk 
dose is limited, so the optimal dose constraints for 
organs at risk are unknown [41]. Additional infor-
mation is needed to clarify the risks and benefits 
of SBRT in oligometastatic and oligoprogressive 
adrenal gland metastases. 
We performed an analysis of our institutional 
experience for SBRT in oligometastatic/oligo-
progressive disease to the adrenal gland with the 
goal of achieving durable local control exclud-
ing patients treated with a purely palliative intent. 
There is a focus on dosimetric analysis of organs 
at risk and on comparing published data to our 
experience. In addition, we investigated whether 




We performed a comprehensive review of Eng-
lish-language literature reporting local control, 
overall survival and toxicity outcomes after adrenal 
metastases SBRT in order to compare our results 
with prior studies. PubMed, EMBASE and Google 
Scholar search tools were utilized. Only peer-re-
viewed final publications were included. Unlike 
Chen et al. [41], abstracts and poster presentations 
were not included as the quality of such data is 
suboptimal. The studies are summarized in Table 1 
[13–40] and include several published reports since 
the Chen et al. meta-analysis was conducted [41].
patient characteristics
We performed a retrospective review from 
our institution of 26 tumors in 23 patients from 
2013–2019 treated with SBRT for adrenal metas-
tases in oligometastatic or oligoprogressive disease 
defined as having between one and five metastatic 
lesions or having multiple lesions that are controlled 
on systemic therapy with one to five lesions that 
progressed [6]. The goal of treatment was primar-
ily durable local control. Treatment administered 
only for palliation of pain were not included. In all 
cases, multidisciplinary tumor board evaluations 
including radiation oncologists, surgical oncolo-
gists, medical oncologists, diagnostic and interven-
tional radiologists and pathologists took place prior 
to treatment. Patients were generally followed every 
3–6 months for the first two years and then 6–12 
months subsequently after the completion of SBRT. 
Detailed electronic medical records were complete 
and available for all patients included in the study.
Treatment technique
For the purposes of our study, SBRT is defined as 
advanced highly conformed radiation using image 
guidance that delivers at least 5 Gray (Gy) in a max-
imum of five to six fractions. In addition, a more 
sophisticated quality assurance procedure was re-
quired for all SBRT treatments than for convention-
ally fractioned radiotherapy treatments. Organs at 
risk (OAR) including the liver, kidneys, stomach, 
spinal cord and bowel were delineated and used as 
avoidance structures. Standard American Associa-
tion of Physicists in Medicine (AAPM) Task Group 
(TG) 101 SBRT quality assurance, delivery and dose 
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constraint guidelines were met [11]. Either Cy-
berknife or RapidArc treatment systems were used 
for SBRT. On RapidArc, volumetric modulated arc 
therapy (VMAT) on a TrueBeam linear accelerator 
(Varian Medical Systems, Palo Alto, CA), 10 mega-
volt (MV) photons were delivered using flattening 
filter-free system and custom multileaf collimators 
(MLC) were used to create a multibeam treatment 
table 1. summary of the published peer-reviewed studies (excluding the abstract presentations) and the current series that 
investigated adrenal sBrT
Author* Year N BED10 1- and 2-year LC
1- and 2-year  
OS
Toxicity
Oshiro 1999–2008 19 65 (65–120) 79% Lc 56% and 33% 5% gr 2 duodenal ulcer, no gr 3–5 tox
chawla 2001–2007 30 56 (22–75) 44% and 27% 55% and 25% No gr 2 tox or greater
shah 2001–2014 44 48 (21–101) 97% Lc
7 mo median 
survival
2% gr 3 gastric ulcer, gr 4–5 tox
casamassima 2002–2009 48 79 (60–100) 90% and 90% 40% and 15% 2% gr 2 adrenal insufficiency, no gr 3–5 tox
holy 2002–2009 18 75 (36–119) 77% Lc
25–80% and 
0–60% 
33% gr 1 nausea, 11% gr 2 GI ulcers




8 38 (28–66) 44% and 44% 52% and 13% No gr 3–5 tox
Burjakow 2003–2015 33 67 (42–109) 58% and 42% 46% and 34% No gr 2–5 tox
scorsetti 2004–2010 34 58 (30–56) 66% and 32% 70% and 52% No gr 3–5 tox
Katoh 2004–2017 12 77 (60–100) 92% and 53% 79% and 46% No gr 2–5 tox
rudra 2005–2009 10 60 (43–79) 73% and 73% 90% and 50% 10% gr 2 tox, no gr 3–5 tox
Desai 2006–2011 14 41 (28–60) 64% Lc Not reported None
haidenberger 2006–2015 23 74 (60–113) 95% and 81% 77% and 72%
22% acute nausea, no other tox,  
no gr 3–5 tox
Zhao 2006–2017 75 80 (45–113) 84% and 62% 63% and 50% 1.5% gr 3 diarrhea, 1.5% gr 3 fatigue
Mills 2007–2018 27 68 (48–113) 77% at 1 year 38% at 1 year 10% gr 2 tox, 4% gr 5 tox: fatal gastric ulcer
Toesca 2008–2017 35 72 (30–125) 92% and 92% 60% and 48% 17% gr 2 tox, no gr 3–5 tox
ahmed 2009–2011 13 86 (60–132) 100% at 1 year 63% at 1 year 23% gr 2 GI tox, no gr 3–5 tox
Li 2009–2012 26 87 (48–113) 77% Lc 62% and 30% 4% gr 2 GI tox, no gr 3–5 tox
Gamsiz 2009–2013 14 60 (60–60) 87% Lc 33% Os 7% gr 2 GI tox, no gr 3–5 tox




10 60 (48–113) 70% Lc 30% and 30% No gr 3–5 tox
Buergy 2010–2017 18 52 (31–144) 77% Lc 60% and 30% No gr 3–5 tox
Franzese 2011–2015 46 80 (80–80) 66% and 41% 88% and 88%
Gr 2 fatigue and GI tox occurred,  




97% and 93% 79% and 60% No gr 3–5 tox
Yaprak 2011–2018 26 60 (29–113) 66% and 66% 50% and 21% 27% gr 1–2 tox, no gr 3–5 tox
celik 2012–2015 15 71 (71–71) 60% and 47% 93% and 67% No gr 3–5 tox
Konig 2012–2019 28 75 (58–151) 85% and 85% 47% and 32% No gr 3–5 tox
Figura 2013–2018 41 72 (38–132) 96% at 1 year 71% and 51% 2% gr 3 hypertensive crisis, no gr 4–5 tox
reshko** 2013–2019 23 72 (40–100) 80% and 80% 66% and 32% 4% gr 2 nausea, no gr 3–5 tox
*first author’s last name; **current series; N — number of patients; BeD10 — median and range of biologically effective radiotherapy dose using an a/b ratio 
of 10; Lc — local control; Os — overall survival; mo — months; tox — toxicity; gr — common Terminology criteria for adverse events (cTcae) grade;  
GI — gastrointestinal
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plan. On Cyberknife image-guided robotic linear 
accelerator (Accuray, Sunnyvale, CA), 6 mega-volt 
(MV) photons with a noncoplanar beam arrange-
ment were utilized.
An individualized motion management technique 
was utilized in every case. Vac-lock immobilization 
was commonly used in RapidArc treatments. A 4D 
simulation with 3-mm slice thickness was performed 
to assess tumor motion. If tumor motion was 10 mm 
or greater, a deep inspiratory or expiratory breath 
hold technique was used. Otherwise, an internal tar-
get volume (ITV) was constructed such that the tu-
mor was included in all ten respiratory phases. Daily 
cone beam CT scans were obtained to confirm setup 
reproducibility on RapidArc. Cyberknife technology 
was used when the tumor had less than 10 millime-
ters (mm) of motion on a four-dimensional (4D) 
simulation scan. Xsight spine tracking was then used 
to align treatment to the bony anatomy using daily 
kilo-volt (kV) orthogonal x-rays. In one case, a fidu-
cial marker was placed for tracking on Cyberknife. 
In that case, an ITV was not necessary as there was 
real-time tumor tracking. Cyberknife treatments 
were prescribed to 70–80% isodose line. For both 
RapidArc and Cyberknife, the planning target vol-
ume (PTV) was obtained by adding an isotropic ex-
pansion of 5 mm from the ITV. On RapidArc, treat-
ments were prescribed such that 95% of the PTV 
received 100% of the prescription dose. A typical 
radiation treatment plan is shown in Figure 1.
Biologically effective dose (BED) was calculated 
by the formula: 
nd[1+d/(α/β)].
Equivalent doses of 2-Gy fractions (EQD2) were 
calculated from the BED with the following for-
mula:
nd[(d+α/β)÷(2+α/β)] [43].
α/β is a ratio unique for a given tissue, d = dose 
per fraction and n = number of fractions. α/β of 10 
was used, and the biologically effective dose with 
this α/β ratio was designated as BED10 [44]. An 
estimated maximum BED10 was calculated by di-
viding the BED10 reported by the percent isodose 
prescribed for the purpose of comparing to the 
studies that reported BED10 in that way. For ex-
ample, a BED10 of 50 prescribed to the 80% isodose 
line would have an estimated maximum BED10 of 
62.5 [41].
Outcome evaluation
Primary endpoint was local control. This was 
defined as no progressive disease according to the 
Response Evaluation Criteria in Solid Tumors (RE-
CIST) (version 1.1) and Positron Emission Tomog-
raphy (PET) Response Criteria in Solid Tumors 
(PERCIST) 2009 criteria in cases when PET/CT 
Figure 1. example of adrenal sBrT treatment on rapidarc LINac. Organs at risk on the dose volume histogram (top right) 
from left to right are: pink — small bowel, yellow — spinal cord, cyan — right kidney, green — liver, and red — planning 
target volume (pTV) adrenal gland
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scans were obtained in follow-up [45]. Treatment 
response to adrenal SBRT was classified as com-
plete response (CR), partial response (PR), stable 
disease (SD), or progressive disease (PD). Second-
ary endpoints were radiotherapy-related toxicity, 
systemic-therapy-free survival and overall survival. 
Treatment-related toxicity was assessed and classi-
fied according to Common Terminology Criteria 
for Adverse Events (CTCAE) v5.0 [46]. Acute tox-
icity included side effects during radiotherapy and 
within three months of SBRT completion and late 
toxicity included events after three months. Other 
data was collected and analyzed including the de-
tailed dosimetry of the tumor and organs at risk, tu-
mor motion, patient’s functional status, tumor size, 
utilization of systemic therapy, surgery or conven-
tional radiotherapy, SBRT dose and fractionation.
statistical analysis 
Kaplan Meier product estimator was used to as-
sess local control, systemic-therapy-free survival, 
overall survival, and progression-free survival. Cox 
proportional hazards regression analysis was used 
to assess the relationship of local control, progres-
sion-free survival, and overall survival with the pa-
tient’s performance score, radiation dose, cancer 
primary, histology, neutrophil to lymphocyte ratio 
(NLR) and tumor stage. Due to the limited number 
of patients, all comparisons are univariate. An in-
sufficient number of patients was enrolled to assess 
correlations with toxicity outcomes, particularly 
given the low number of radiation-induced side 
effects. All analyses were performed using the R 
project for statistical computing software, version 
3.6.2. Significance was defined as α < 0.05.
results
patient characteristics
All the patients included in our study and their 
clinical characteristics are shown in Table 2 and Ta-
ble S1 — Supplementary File. Various tumor types 
and initial stages/treatments were represented but 
the majority were lung primaries. Most patients had 
an Eastern Cooperative Oncology Group (ECOG) 
Performance Status of either 0 or 1 with only 13% 
of patients having an ECOG of 2. The median age 
was 66 (range: 42–79). Most patients had major 
comorbidities, especially coronary artery disease, 
chronic obstructive pulmonary disease and hyper-
tension. Most patients were smokers with a median 
of 57 pack-year history (range: 5–120) with only 
35% of cases presenting with no history of tobacco 
use. The median follow-up was 12 months with 
an interquartile range of 7 to 20 months. Prior to 
SBRT, 91% of patients received systemic therapy, 
48% underwent surgical resection and 70% under-
went radiotherapy. 31% of SBRT treatments were 
administered due to oligometastatic disease and 
the remaining 69% were for oligoprogressive dis-
ease with systemic therapy held during SBRT and 
resumed after its completion. 
Dosimetry
The detailed dosimetric parameters are shown in 
Table 3. The median dose was 36 Gy in 3 fractions 
(range: 24–50 Gy and 3–6 fractions) with a median 
BED10 of 72 (range: 40–100) for an α/β ratio of 10. 
40 Gy in four fractions was the second most com-
mon approach and was used in 15% of treatments. 
When adjusting for the prescription isodose line of 
80%, as was done in a recently published meta-anal-
ysis [41], estimated maximum BED was 100 (for the 
most commonly used regimen of 36 Gy in 3 frac-
tions). The median time from diagnosis to SBRT 
was 31 months (range: 1–184 months). The me-
dian follow-up time after treatment was 12 months 
(range: 3–44 months). Lower radiation doses were 
used in cases when there was a concern for nearby 
organs at risk, particularly the kidney and bowel. 
There was a significant variation in radiation dose 
to the liver, kidney, stomach, spinal cord and bowel 
depending on each patient’s anatomy, tumor loca-
tion and size of the adrenal metastasis. There was 
a large variation in tumor size with a median tumor 
volume in cubic centimeters of 30 (range: 3.6–157) 
and largest tumor dimension ranging from 1.2 to 
8.4 centimeters.
Local control, overall survival, 
progression-free survival  
and systemic therapy-free survival 
The median local control could not be deter-
mined as there was an insufficient number of local 
failures. The median overall survival was 20 months 
(range 3–44 months), progression-free survival, 18 
months (range 6–36 months) and systemic-ther-
apy-free survival, 7 months (range 2–25 months). 
The Kaplan-Meier curves for local control, overall 
survival, progression-free survival, systemic thera-
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py-free survival are shown in Figure 2. While local 
control was achieved in 85% of treated tumors and 
87% of treated patients, only 13% of patients had 
no evidence of active disease and 13% had a stable 
disease status at last follow-up. The remainder of 
patients had progressive distant metastases. 39% 
of the patients with progressive disease were de-
ceased by the last follow-up. Superior performance 
status and higher BED10 were associated with bet-
ter overall survival [hazard ratio (HR): 0.51, 95% 
CI: 0.27–0.97, p = 0.041 and HR: 0.73, 95% CI: 
0.54–0.98, p = 0.039, respectively). Higher BED10 
was also associated with better progression-free 
survival (HR: 0.69, 95% CI: 0.52–0.92, p = 0.010) 
as shown in Table 4. Higher neutrophil to lympho-
cyte ratio (NLR) was associated with worse survival 
(HR: 1.09, 95% CI: 1.01–1.18, p = 0.023). There was 
a trend toward progression-free survival detriment 
with higher NLR (HR: 1.07, 95% CI: 0.99–1.15, 
p = 0.068) as seen in Table 4. Tumor size, stage, pri-
mary tumor origin and tumor histology were not 
associated with overall or progression-free survival. 
No variable was associated with local control but 
there were only four local failure events making the 
statistical analysis suboptimal. 
Toxicity
Acute side effects included grade 1 nausea in 
five treatments and grade 1 fatigue in one case. 
Only one grade 2 toxicity occurred — nausea. This 
was treated effectively with anti-nausea medica-
tions. There was only one instance of late toxicity 
table 3. continued
Pt Lesion PTV 95% PTV min PTV max PTV mean Stomach D10cc Spinal max
1 1 36.0 17.7 42.8 39.8 8.5 9.6
2 2 30.0 23.4 38.0 34.5 N/a 7.8
3 3 36.0 27.6 42.6 39.4 11.4 12.6
4 4 40.0 21.8 50.2 43.2 16.3 10.9
5 5 24.0 16.5 29.6 26.8 16.3 6.8
6 6 30.0 20.3 35.8 32.8 19.5 7.7
7 7 30.0 26.3 35.1 32.3 0.36 0.4
8 8 24.0 21.2 28.3 26.0 19.2 5.8
9 9 22.4 17.9 27.8 24.7 6.4 4.8
9 10 20.3 17.2 26.0 22.9 3.1 3.9
10 11 36.0 32.6 43.1 37.9 3.0 6.6
11 12 49.7 45.4 69.4 57.2 31.3 13.9
12 13 23.7 20.1 34.3 29.0 9.6 8.7
12 14 23.7 20.1 34.3 29.0 9.6 8.7
13 15 40.0 29.0 51.3 44.7 18.0 12.9
14 16 33.5 30.9 51.5 40.6 7.7 17.5
15 17 30.0 27.7 37.0 33.1 12.2 7.5
16 18 34.6 14.5 46.2 40.0 15.7 5.2
17 19 35.9 31.4 46.8 40.9 11.0 7.5
17 20 24.6 12.6 60.0 45.9 13.2 9.5
18 21 40.0 30.2 51.1 44.9 7.7 9.0
19 22 40.0 37.5 44.7 41.8 5.3 7.4
20 23 30.0 27.2 34.4 32.3 5.7 9.7
21 24 36.1 24.5 42.1 39.2 5.9 6.4
22 25 36.0 30.2 42.4 38.8 4.0 5.7
23 26 36.1 10.0 45.6 41.0 14.4 12.2
pt — patient; pTV 95% — radiation dose in Gray (Gy) to the 95% of the planning target volume (pTV); pTV min — the lowest radiation dose within the pTV, 
pTV max — the highest radiation dose within the pTV; pTV mean — the mean radiation dose within the pTV; stomach D10cc — radiation dose to the 10 cubic 
centimeters; spinal max — the highest radiation dose to the spine
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— grade 1 adrenal insufficiency. This was noted on 
the follow-up laboratory evaluation. The patient 
remained asymptomatic and did not require any 
treatment. No instances of grade 2 or higher late or 
grade 3 or higher early toxicity were noted.
subsequent treatments
After SBRT, 83% of the patients required sub-
sequent treatment for progressive disease. Most 
patients received additional cancer treatments af-
ter the completion of adrenal SBRT including 70% 
who received systemic therapy, 39% who received 
radiotherapy and 9% who underwent surgical pro-
cedures. 48% of patients received immunotherapy. 
Other radiation therapy regimens given after the 
completion of adrenal SBRT included spine SBRT, 
lung recurrence SBRT, postoperative fractionated 
radiotherapy for a humerus pathology fracture, 
electron beam radiotherapy for a chest wall mass, 
and radiosurgery, fractionated stereotactic radio-
therapy and whole-brain radiation for brain me-
tastases. Systemic therapy after the completion of 
adrenal SBRT included immunotherapy (atezoli-
zumab, nivolumab, pembrolizumab), targeted 
agents (plinabulin, regorafenib, erlotinib, ceri-
tinib, debrafenib and trametinib) and traditional 
Figure 2. Outcomes of patients treated with sBrT to the adrenal gland oligometastatic/oligoprogressive disease: A. Overall 
survival; b. Local control; c. progression-free survival; D. systemic therapy-free survival
a B
c D
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chemotherapy (docetaxel, paclitaxel, carboplatin, 
capecitabine, temozolomide and etoposide).
Discussion
patient characteristics
Many prior reports on adrenal SBRT suffer from 
several deficiencies. Many of the studies included 
in the recent Chen et al. meta-analysis are only 
published in an abstract form and one was a thesis 
which have not been published in a peer-reviewed 
journal [41]. Moreover, there was significant het-
erogeneity in the different studies cited particu-
larly regarding motion management, years when 
the studies were conducted, and palliative com-
pared to durable local control intent of SBRT. Un-
like many of the studies that included palliative 
cases with widely metastatic disease [14, 20, 29, 
34, 38], we only included cases with oligometa-
static or oligoprogressive disease. One retrospective 
analysis showed a median survival of 1.6 months in 
polymetastatic, 6.5 months in oligoprogressive and 
33 months in oligometastatic disease patient [34]. 
These variations underscore the need to stratify 
patients [6–8]. Moreover, the meta-analysis was 
conducted at a study level and not a patient level 
[41]. There is very limited prospective data on ad-
renal metastases SBRT. Unfortunately, low sample 
size of adrenal metastases in these studies makes 
comparison challenging [8–10, 47]. Because of 
these limitations, final publications of individual 
institutional experience remain relevant and useful 
in clinical practice. Compared to the other stud-
ies shown in Table 1, our series represents a more 
modern population. This is relevant to patient out-
comes and treatment tolerance as there have been 
major improvements in systemic therapy, imaging 
and radiotherapy technique — particularly motion 
managementThere was significant dose and frac-
tionation heterogeneity among the various studies 
of adrenal SBRT. Many reports included regimens 
which do not meet the typical definition of SBRT 
as described in the Methods such as 45 Gy in 18 
fractions [21]. However, in our study every patient 
received an SBRT regimen. In phase 2 randomized 
trials, Palma et al. only treated adrenal metastases 
in 5% of their reported cases — all with 60 Gy in 
8 fractions [12], Iyengar et al. treated three cases 
using 30 Gy in 5 fractions [10] and Gomez et al. 
only reported one adrenal metastasis treated with 
SBRT with 60 Gy in 8 fractions [9]. The BED10 
of 30 Gy in 5 fractions is 48 Gy compared to the 
BED10 of 105 Gy with 60 Gy in 8 fractions. In 
retrospective studies, there was a huge variation in 
table 4. statistical analysis
Variable Demographics**
Local control Overall survival Progression free survival
HR CI p-value HR CI p-value HR CI p-value
Kps* 89 10 1.25 0.37 4.21 0.721 0.51 0.27 0.97 0.041 0.69 0.39 1.21 0.198
BeD* 64 17 0.63 0.34 1.17 0.145 0.73 0.54 0.98 0.039 0.69 0.52 0.92 0.010
primary
   Lung 13 50% ref ref ref
  Other 13 50% 1.13 0.16 8.04 0.904 0.65 0.23 1.86 0.425 0.82 0.32 2.09 0.671
histology
  ac 11 42% ref ref ref
  Other 15 58% 0.70 0.10 4.98 0.719 1.26 0.43 3.70 0.678 1.02 0.39 2.63 0.976
stage
  1 3 12% 2.06 0.29 14.83 0.474 1.18 0.13 10.85 0.885 2.86 0.51 15.95 0.231
  2 6 23% ref 2.75 0.67 11.30 0.160 4.52 1.25 16.26 0.021
  3 6 23% 0.00 – – – 0.67 0.19 2.40 0.540 0.68 0.19 2.45 0.554
  4 11 42% 0.00 – – – ref ref
NLr 7.2 7.7 0.47 0.12 1.83 0.280 1.09 1.01 1.18 0.023 1.07 0.99 1.15 0.068
size* 51 57 0.91 0.67 1.23 0.531 1.06 0.97 1.17 0.204 1.05 0.96 1.15 0.298
*To assist interpretation, the hrs for these variables (Kps, BeD and tumor size) correspond to a 10-unit change; **Demographics are report as mean and standard 
deviation for quantitative variables and number and proportion of tumors per category for qualitative variables; hr — hazard ratio; cI — confidence interval for 
hazard ratio; Kps — Karnofsky performance status; BeD — biologically effective dose; ref — reference category; NLr — neutrophil to lymphocyte ratio
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dose and fractionation used – BED10 ranged from 
21 to 144 [13–40]. Dose and fractionation regimen 
such as 30 to 36 Gy in 3 fractions [26, 27, 36], 34 to 
60 Gy in 5 fractions [17, 28, 29], and 60 to 70 Gy 
in 10 fractions were used [22]. Some investigators 
even reported single-fraction treatments with doses 
ranging from 14 to 27 Gy [15, 16]. Prospective 
studies of adrenal SBRT, such as the Italian phase II 
trial using 45 Gy in 3 fractions [48], are needed to 
further clarify which dose/fractionation is optimal.
patient outcomes
Our median follow-up time of 12 months is 
comparable to other studies [14, 26, 29]. 1-year 
local control rate was 80%. In the meta-analysis 
by Chen et al., there was no statistically significant 
association between tumor histology, size and local 
control of adrenal metastases. Higher maximum 
BED10 correlated with improved local control and 
overall survival [41]. Similarly, in our patients, 
higher BED10 was associated with improved over-
all survival and progression-free survival. There 
was a trend toward better local control with higher 
BED10 which was not statistically significant likely 
due to a low number of local failures (HR: 0.63, 
95% CI: 0.34–1.17, p = 0.145) as shown in Table 3. 
Given that a median BED10 of 72 and an estimated 
maximum BED10 of 100 (using the median radia-
tion dose/fractionation of 36 Gy in 3 fractions, α/β 
of 10 and dividing by 0.8 to account for the 80% 
isodose line prescription) was used in our study, 
a 1-year local control rate of 93% would be expected 
— similar to what was found in our patients [41]. 
Zhao et al. is the largest series of adrenal metas-
tases SBRT with 75 patients. They found a 1-year 
local control of 84% with a median BED10 of 80 
[26]. Toesca et al. has the longest follow-up time 
of any study with a median follow-up time of 37 
months. They reported similar BED10 used with 
a median of 72. Their local control rates were excel-
lent at 92% in 1 year [28]. Casamassima et al. is an 
older study including 48 patients treated between 
2002 and 2009. The median BED10 was 79 with 
a 1-year local control of 90% [16]. Chawla et al. 
is another study performed during a similar time 
period. However, lower radiation doses were used 
with a median BED10 of 56. The 1-year local con-
trol was suboptimal at only 44% [14]. Scorsetti et 
al. is another study that used lower median BED10 
of 58. The resulting 1-year local control was less 
than ideal at 66% [21]. There is evidence that there 
is improved local control and overall survival with 
increased dose of SBRT [41]. Scouarnec et al. is one 
of the most recent studies, used the largest BED10 
of any other report — 113 and had one of the high-
est 1-year local control rates reported — 97% [36].
In our study, the 1- and 2-year overall survival 
rates were 66% and 32%. The median survival in 
other retrospective studies is reported to be be-
tween 8 and 23 months [13–29], consistent with 
the prospective reports of oligometastatic cancer 
[8–10]. The median survival in our study is 20 
months comparing favorably with the prior re-
ports. Similar to the prior studies, while local con-
trol at two years was 80%, the progression-free 
survival was only 30% due to the distant progres-
sion of metastatic disease. Consistent with the 
meta-analysis, overall survival was associated with 
increased BED10 delivered to the adrenal metasta-
ses [41]. Moreover, higher Karnofsky Performance 
Status (KPS) was associated with improved sur-
vival. Our study was not designed to evaluate the 
impact of specific systemic therapy on survival, 
but further improvement would be expected with 
superior control of distant metastatic disease. The 
use of SBRT and immunotherapy is a particularly 
promising combination [7, 12].
A reasonable progression-free survival (median 
of 18 months) and systemic therapy-free survival 
(median of 7 months) rates were noted in our study. 
This is an important variable for patients who may 
have a limited number of systemic therapy options 
left. Moreover, longer progression-free and system-
ic therapy-free intervals mean fewer side effects re-
lated to chemotherapy, immunotherapy or biologic 
agents. While indications for initiation of chemo-
therapy, targeted therapy or immunotherapy after 
SBRT in oligometastatic disease is beyond the scope 
of this work, the results presented here demonstrate 
that a considerable systemic therapy-free interval 
may be achieved in many patients.
radiotherapy-induced toxicity
Treatment-related toxicity in our patient popula-
tion was very low with only grade 1 and 2 events 
observed. In the Chen et al. meta-analysis, the over-
all rate of grade 3 or greater toxicity was also low at 
1.8% [41]. In that study, radiation dose, tumor later-
ality, proportion of bilateral tumors treated, tumor 
size and motion management techniques were not 
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associated with increased toxicity — which could 
be due to a heterogeneity of tumor types, SBRT 
dose and fractionation as well as lower than ideal 
number of patients. While renal dysfunction and 
adrenal insufficiency are often feared complications 
of SBRT to the adrenal metastases, very few patients 
were reported to have these side effects [41]. Un-
fortunately, toxicity outcomes have been reported 
inconsistently. It is often not specified whether side 
effects were acute or chronic. A limited follow-up 
and low numbers of patients in each study of ad-
renal SBRT limits the analysis. Some studies even 
included as few as seven patients [41]. Fortunate-
ly, grade 4 and 5 toxicity are extremely rare and 
only three cases were reported. The one patient 
reported in the meta-analysis who died had been 
treated with nivolumab while receiving SBRT [41]. 
Interestingly, the only patient in our study who 
developed grade 2 toxicity — nausea — was treated 
with immunotherapy immediately prior and soon 
after the completion of adrenal SBRT. However, the 
number of patients enrolled in our study is clearly 
too low to analyze the impact of immunotherapy 
on toxicity.
Other factors
The effect of inflammation on clinical outcomes 
of patients treated with SBRT has been investigated 
in various malignancies. Neutrophil to lymphocyte 
ratio (NLR) has been shown to be an effective sur-
rogate of inflammation [49]. High NLR was shown 
to be associated with worse survival of patients 
treated with SBRT [50]. In a recent single-institu-
tional study, NLR was shown to be correlated with 
outcomes of patients with adrenal metastases treat-
ed with SBRT27. In our study, there was likewise an 
association between higher NLR and worse overall 
survival and a trend toward worse progression-free 
survival (HR: 1.07, 95% CI: 0.99–1.15, p = 0.068) as 
shown in Table 4. While further studies are needed 
to confirm this association, these findings provide 
additional evidence that inflammation is associated 
with clinical outcomes in patients with adrenal me-
tastases treated with SBRT.
There is a lack of detailed data on radiation treat-
ment dosimetry in many of the prior studies [16, 
32, 41]. Detailed dosimetric information about 
normal tissue and PTV dose is available on all the 
patients treated in our study as shown in Table 3. 
There is a notable variability of doses to the or-
gans at risk and tumors. While the primary tumor 
location, histology, stage and tumor size did not 
correlate with overall survival or progression-free 
survival, the number of patients enrolled in our 
study is likely insufficient. Local control assessment 
was particularly limited by the small number of 
local failures. While our study was not designed 
to evaluate the impact of motion management, the 
techniques used at our institution allowed for ac-
curate tumor tracking which likely contributed to 
good local control.
Limitations
While this study provides important data in an 
area of research where there is paucity of prospec-
tive studies and no consensus among experts, there 
were several limitations. Our sample size is rela-
tively small and included a relatively heterogeneous 
patient sample of various primary malignancies. 
Polymetastatic and palliative cases were excluded, 
though, which makes our sample more homoge-
neous than most prior studies. Subgroup analyses 
are particularly affected by a limited number of 
patients. Moreover, since patients over a span of 
ten years were included in this study, changes in 
oncologic management occurred — particularly 
the systemic therapy selection. Adrenal SBRT is 
a relatively rare procedure and unless it becomes 
more commonly used, recruiting more patients 
over a shorter time span would require a multi-in-
stitutional investigation. A large prospective study 
is needed to further evaluate the safety and effi-
cacy of this technique. This study is retrospective 
which limits our ability to determine how much 
of the tumor control, toxicity and survival benefit 
was specifically due to SBRT. Another limitation 
is the variation in systemic therapy, surgical and 
radiotherapy regimens prior to SBRT treatments. 
While the medial follow-up time of 12 months is 
comparable to the other studies, it is still relatively 
short and is a limitation when it comes to assessing 
toxicity. Also, this study does not compare the ef-
ficacy of SBRT to other possible modalities such as 
conventionally fractionated radiotherapy, brachy-
therapy, radiofrequency ablation, surgical resection 
and systemic therapy alone. 
Future directions
At least 14 studies on adrenal SBRT for metastat-
ic disease are in an abstract form [41]. Final publi-
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cations are needed to fully evaluate those reports. 
Prospective studies will further evaluate the safety 
and efficacy of adrenal gland SBRT. An ongoing 
Italian phase 2 study by Istituto Clinico Humani-
tas will provide important data [48]. In addition, 
there are several large prospective studies including 
SABR-COMET 10, SARON and NRG-BR002 that 
are investigating SBRT for oligometastatic disease 
to various sites including the adrenal gland [12, 51, 
52]. A combination of SBRT and various types of 
immunotherapy needs to be further explored. En-
couraging results, particularly in PD-L1-negative 
tumors, were recently reported in the PEMBRO-RT 
trial [53], but additional studies are needed to clar-
ify which patients benefit from a combination of 
SBRT and immunotherapy. The role of inflamma-
tion in patients treated with SBRT to the adrenal 
gland needs to be further studied as well. New tech-
nology, such as MR-guided radiotherapy, is prom-
ising. MRI guidance is expected to help manage 
adrenal tumor respiratory motion [54]. Moreover, 
further studies are needed to characterize the re-
sponse to SBRT in specific oligometastatic disease 
states including synchronous, metachronous, oli-
gorecurrent, oligoprogressive and oligopersistent 
disease [6].
conclusions
Adrenal SBRT for oligometastatic or oligopro-
gressive disease is a safe and effective form of treat-
ment. While good local control and reasonable 
progression-free and systemic therapy-free survival 
rates can be achieved with this technique, distant 
metastatic disease progression remains a concern 
limiting overall survival. Our findings are consis-
tent with the data reported in multiple prior retro-
spective studies. Prospective studies are needed to 
validate these findings.
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